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Experience in Imaging Medullary Thyroid Carcinoma Using ^^ ""Tc (V) 
Dimercaptosuccinic Acid (DMSA) 
Susan Clarke,* Colin Lazarus,* and Michael Maisey* 
wmj^ (V) dimercaptosuccinic acid (DMSA) is a new tumor imaging agenl that has been successfully 
used to image patients with medullary thyroid carcinoma (MTC). Since 1986, studies have been 
performed in 32 patients wilh histologically proven MTC al Guy's Hospital, London, England. Five 
patients with primary tumor were studied prior lo surgery, four patients were studied after successful 
removal oflhe primary tumor, and 26 patients with biochemical evidence of recurrence were studied. 
Eight patients were studied serially to assess progression of disease, and four patients were studied 
before and afler surgery. Twenty-one of the 26 patients with disease had positive scans with four false-
negative scans and three true negative scans. One patient had a false-positive scan (sensitivity 80%, 
specificity 75%). Two of the false-negative scans were obtained in patients wilh moderate but stable 
elevations of calcitonin hut no olher evidence of recurrence. One false-negative scan was obtained in a 
patient who was discovered on screening to have an abnormal pentagastrin response, and a small 1 cm 
tumor was subsequently removed. Uptake in local neck recurrence was frequently interne, but uptake 
at sites of bone metastases was less marked. '^'"Tc (V) DMSA is an inexpensive radiopharmaceutical 
which produces good quality images and has been shown to have an acceptable sensitivity and 
specificity in the follow-up of patients with MTC and ihereby contributes significantly to the 
management of these patients. (Henry Ford Hosp MedJ 1989;37:167-8) 
I n 1984 Ohta et al (I) reported their experience of imaging pa-tients with known malignancy using a newly developed tech-
netium 99m-labeled radiopharmaceutical, pentavatent dimer-
captosuccinic acid ([V] DMSA). Of the parients imaged, five 
had medullary thyroid carcinoma (MTC) and alt showed uptake 
of'"^Tc (V) DMSA in their tumors. Other groups have atso re-
ported success in imaging patients with MTC. In 1988 Patel et al 
(2) reported 15 MTC patients and showed positive localization in 
80% of those studied. In 1989 Guerra etal (3) studied 26 patients 
with MTC using '^ '"Tc (V) DMSA and showed a sensitivity of 
84.2% for the technique. Following the 1987 report of our expe-
rience using '''^ "'Tc (V) DMSA to image ten parients with MTC 
when a sensitivity of 80% was achieved (4), we now report our 
four-year experience of using '^ "'Tc (V) DMSA in routine man-
agement of patients with histologically proven MTC. 
Patients and Methods 
The 32 parients studied included ten mates and 22 females 
ranging in age from 14 to 86 years. Of these patients, 26 had 
sporadic MTC, four had multiple endocrine neoplasia type 2A 
(MEN 2A), and two had MEN 2B. Five patients with primary 
tumors were studied prior to surgery, four patients were studied 
after successful removal of the primary tumor, and 26 patients 
with biochemical evidence of residual or recunent tumor were 
studied. Eight patients were studied serially to assess the pro-
gression of disease, and four were studied before and after sur-
gery. A total of 56 scans were performed. Alt patients were eval-
uated by '""'Tc medronate methylene diphosphonate (MDP) 
bone scans, chest roentgenograms, and computed tomography 
to define accurately the extent of their disease. 
•"•"Tc (V) DMSA was prepared using the previousty reported 
method (4) and labeled with 370 MBq (10 mCi) of '"-"Tc. Fol-
lowing intravenous administration, whole body images were ac-
quired at 3 hours using a large field of view gamma camera and a 
general all-purpose collimator. No image enhancement was 
used, although singte photon emission computed tomography 
(SPECT) was perfonned in two patients to define accurately the 
extent of their neck recunence before surgery. 
Results 
Uptake of''"Tc (V) DMSA varied from intense to slight. Up-
take in small lesions less than 1 cm and in bone metastases was 
usually less than the uptake in soft fissue disease. Of the five 
patients with primary tumors, one patient showed no significant 
uptake in the thyroid. This 17-year-old girl, the sibling of a 
known case of MEN 2A, had an abnormal calcitonin (CT) re-
sponse to pentagastrin. At surgery a smalt focus of MTC, about 
1 cm in diameter, was discovered. The other four patients with 
primary tumors showed positive uptake on imaging, and in two 
patients involved local lymph nodes were atso imaged. 
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In the patients studied postoperatively, the four patients with 
successful removal of tumors had negative scans. In two other 
patients studied postoperatively, involvement of mediastinal 
nodes necessitated sternal splitting to approach the medi-
astinum. Postoperative scans showed uptake in both patients in 
unresectable tumor and atso in the stemum at tbe site of surgery. 
Two pafients were studied following radiotherapy to the neck, 
and both showed tow grade diffuse uptake in the neck within the 
radiotherapy field. 
Ofthe 26 patients studied with biochemical evidence of recur-
rence, four patients had false-negative studies with no abnormal 
uptake of ''"Tc (V) DMSA visualized. Three of the four patients 
had stable CT levels, and no disease could be imaged despite 
extensive investigarion with computed tomography and ""Tc 
MDP bone imaging. In one pafient with diffuse lung metastases, 
uptake was initially negative but subsequently became positive 
as the metastases increased in size. The remaining 22 patients 
had uptake on imaging. The degree of ""Tc (V) DMSA ac-
cumulation varied with site of uptake, and uptake in sites of neck 
recurrence was frequently intense whereas uptake in bone me-
tastases was tess marked and frequently identified only when the 
""Tc (V) DMSA study was reviewed with a ""Tc diphospho-
nate bone scan. 
Discussion 
No successful treatment cunently exists for the management 
of some MTC patients. Surgery of the primary tumor, if per-
formed early before local lymph nodes become invotved, may 
be followed by a tong disease-free interval. Primary surgery 
when local lymph nodes are invotved, however, remains only 
palliative despite attempts at extensive neck and mediastinal re-
sections. The slow-growing nature of tumor has encouraged 
many surgeons to attempt extensive dissections to debulk the tu-
mor, reduce symptoms caused by vasoactive peptides, and give 
the patient several years of relative symptom-free existence. 
Other therapeutic options tried in recent years but with little suc-
cess inctude extemal beam radiotherapy, chemotherapy, and " ' I 
meta-iodo-benzylguanidine therapy (5,6). One of the main 
problems in the assessment of new therapies for this disease is 
the inability to define accurately the extent and activity of the 
disease and therefore to assess its response to therapy. Radio-
nuclide techniques such as ""Tc diphosphonate bone scanning, 
""Tc colloid, and ""Tc pertechnetate gtucoheptonate have been 
shown to be sensifive techniques for idenfifying metastatic dis-
ease in the bone, liver, and brain, respectivety, but do not accu-
rately define the extent of the primary disease or local recur-
rence, -"'thallous chloride has been used to image MTC (7,8), 
but although uptake in the primary tumor or tocal recunence is 
marked, the normal biodistribution of ''^ 'thallous chloride in the 
myocardium, lungs, and liver significantly diminishes the 
usefulness of this agent to image metastases in these sites. 
Both ultrasound and computed tomography may be used to 
assess the neck for recunence, but their specificity is low when 
assessing the involvement of lymph nodes, which are frequently 
enlarged secondary to inflammatory change rather than meta-
static involvement. Surgery with major neck and mediastinal 
dissection atso produces gross distortion of the normal anatomy 
and may make interpretation of both computed tomography and 
ultrasound images difficult. Therefore, there is a need for an 
imaging technique that witt accurately define the extent and ac-
tivity of primary and metastatic disease so that as new 
therapeutic agents are developed their efficacy may be readity 
assessed. ""Tc (V) DMSA is inexpensive and can be easily pre-
pared in most nuclear medicine departments. Because there is 
littie nonspecific uptake of the agent, it produces excellent im-
ages which require no processing. It is also an ideal agent for 
SPECT studies, although SPECT is usually unnecessary be-
cause of the high uptake visualized on most planar studies. 
False-positive images do occur following radiotherapy and 
surgery involving bones, but awareness of this usually resolves 
the problem when interpreting a posttherapy image. False-nega-
tive images occur when tumor volume is small, which in our 
opinion is atso the cause of false-negative studies in the well rec-
ognized group of patients whose CT levels fait to fall to the nor-
mal range in the postoperative period and remain elevated but do 
not increase. This phenomenon may partly explain the negative 
results reported by Hitditch et at (9). 
""Tc (V) DMSA has been demonstrated in an increasing 
number of patients to be the imaging method of choice in the 
follow-up of patients with MTC to define accurately the pres-
ence and extent of disease. 
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